Tag Archives: JWN

Best Growth Stocks To Buy Right Now

ICICI Direct’s research report on Titan Company

The management, in its latest BSE filings, has said that the company has undergone a vision exercise to rejig its revenues for FY23E. The management had earlier guided to grow its jewellery revenues at a compounding rate of 20% till FY22 (2.5x revenues of FY17). The same growth phase has now been extended to FY23. Given the robust performance....More>>>

Top 5 Growth Stocks To Buy For 2018

Walmart (WMT) delivered a revenue and earnings beat last week. The company reported revenue of $122.7 billion and eps of $1.14. The stock fell about 1% post-earnings despite exceeding analysts’ expectations. I had the following takeaways on the quarter.

E-Commerce Was The Superstar …

Wal-Mart generated 4% growth Y/Y. Low single-digit growth could be considered adequate....More>>>

Hot Clean Energy Stocks To Invest In 2018

Natural gas for transportation supplierClean Energy Fuels Corp(NASDAQ:CLNE) reported earnings on May 10, and while the company was profitable on both a GAAP and adjusted basis, growth — measured in gallons of natural gas delivered — slowed to almost a trickle, even when adjusted for last year’s sale of the biomethane business. At the same time, the cyclical nature of its station....More>>>

Top Growth Stocks To Watch For 2019

Speculation that Bitcoin mining will lead to “uncontrolled growth” in electricity consumption may be overblown, recalling the hype that surrounded projections for data centers and marijuana growing.

While Bitcoin miners currently use about as much electricity as Ireland, they are "very unlikely" to reach the "ultra-high-end" threshold of 350 terawatt-hours....More>>>

Top 5 Growth Stocks To Buy For 2018

Valeant Pharmaceuticals (NYSE:VRX) is by no means a healthy company. Investing in them is by no means for the faint of heart. Since hitting highs of $259.98 on August 4th, 2015, VRX has been a deathtrap for investors, losing 95% of its market value. There are many reasons for that decline, but I am not going to go directly into all of them. This article is about the future for VRX, and there will....More>>>

Top Growth Stocks To Watch For 2019

Darren Woods is breaking with tradition to become the first Exxon Mobil Corp. CEO to sit in on quarterly conference calls with analysts. But it’s not happening until next year.

Woods, who rose to chief executive in early 2017, will participate in the company’s fourth-quarter earnings call, typically in late January or early February, Vice President of Investor Relations Jeff....More>>>

Hot Growth Stocks To Watch Right Now

Equities analysts expect that Cabot Oil & Gas Co. (NYSE:COG) will post earnings per share of $0.21 for the current quarter, Zacks Investment Research reports. Seven analysts have made estimates for Cabot Oil & Gas’ earnings, with estimates ranging from $0.15 to $0.29. Cabot Oil & Gas reported earnings of $0.14 per share during the same quarter last year, which indicates a positive....More>>>

Best Growth Stocks To Buy Right Now

Brokerages expect OneMain Holdings, Inc. (NYSE:OMF) to report $1.14 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Six analysts have provided estimates for OneMain’s earnings, with the highest EPS estimate coming in at $1.24 and the lowest estimate coming in at $1.03. OneMain posted earnings per share of $0.81 during the same quarter last year, which....More>>>

Top 10 Growth Stocks To Invest In 2019

Yelp Inc. (NYSE: YELP) has performed incredibly over the past year with shares up over 60%, but this is also withstanding a pullback of about 10% in 2017 alone. However, Credit Suisse believes that the pullback is over and that the stock is only going up from here.

Credit Suisse’s Paul Bieber and Stephen Ju reiterated an Outperform rating and with a $49 price target. Keep in mind that....More>>>

Hot Growth Stocks To Watch Right Now

Depomed CEO Arthur Higgins

Depomed (DEPO) delivered a Q1 revenue growth of 42% and EPS growth of over 200%. Growth was spurred by $84 million in revenue from Depomed’s recent commercialization agreement with Collegium Pharmaceutical (COLL) pursuant to pain drug Nucynta. Going forward Collegium will record revenues and all responsibilities for commercializing and distributing Nucynta.....More>>>